Skip to content
MS
unreviewed

Acyl-CoA dehydrogenase (VLCAD/LCAD/MCAD/SCAD)

1 reactions · 1 pathways

Clinical / pharmacological. MCAD deficiency: hypoketotic hypoglycaemia, dicarboxylic aciduria, SIDS-like presentation

What it does, reaction by reaction

1 reactions

Beta-Oxidation of Fatty Acids Lipid Metabolism · Mitochondrial matrix (peroxisome for VLCFA)

step 5 Irreversible/directional

Fatty acyl-CoA + FAD → trans-Δ2-enoyl-CoA + FADH2

Converts Fatty acyl-CoA FAD into trans-Delta-2-Enoyl-CoA FADH2

Notes

An acyl-CoA dehydrogenase catalyzes the first recurring oxidation. Very-long-, long-, medium-, or short-chain acyl-CoA dehydrogenase is selected by chain length; electrons pass from FADH2 through electron-transfer flavoprotein (ETF) and ETF:ubiquinone oxidoreductase to the ubiquinone pool. This is not directly ATP-producing but yields respiratory-chain reducing equivalents.

Showing all 1 reactions.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

1 entries

Beta-Oxidation of Fatty Acids

Listed there as: Acyl-CoA dehydrogenases (including MCAD)

Accelerated by

ADP demand, NAD+/FAD regeneration, substrate supply

Inhibited by

High NADH/NAD+ ratio; respiratory-chain impairment

Hormonal control

Fasting hormones increase fatty-acid delivery; transcriptional control is mediated partly by PPARα in liver

Recent literature

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Integrated transcriptome and metabolome reveal <i>Mycoplasma hyopneumoniae</i> -induced lipid accumulation, inflammation, oxidative stress, and energy imbalance in the liver of pigs.

    Xue X, Bu Y, Yu C, Li J, Yang J, Gao M, Wang P, Gan Y, Zhang W, Fan S, Zhou R, Yin Z, Zheng X. · 2026-06-03

    open access unreviewed
  2. 2
  3. 3
  4. 4
    Natural Plant-Derived Compounds Targeting Oxidative Stress and Inflammation in NAFLD-Mechanisms and Repositioning Potential.

    Theodorou RE, Vrettos N, Theodosis-Nobelos P. · 2026-04-29

    open access unreviewed
  5. 5
  6. 6
    Clinical, Biochemical and Molecular Characterisation of Newborns With Fatty Acid β-Oxidation Disorders: Novel Variants in the ACADM , ACADVL and SLC22A5 Genes.

    Hidalgo Mayoral I, Herranz Cecilia A, Rodríguez-Jiménez C, Carazo Álvarez A, Bergua Martínez A, Andrade Guerr… · 2025-09-29

    unreviewed
  7. 7
    Two Years of Expanded Newborn Screening in Russia: High-Throughput Detection of Inherited Metabolic Disorders by Tandem Mass Spectrometry with Next-Generation Sequencing Confirmation.

    Zakharova EY, Baydakova GV, Baranova PV, Aleksandrova DY, Shchagina OA, Itkis YS, Milovanova NV, Nagornova TS… · 2026-03-02

    open access unreviewed
  8. 8
    Activation of IRF3 in cardiomyocytes impairs mitochondrial oxidative function through PGC-1α inhibition and drives heart failure.

    Kumari M, Evangelakos I, Deshpande A, De Jong KA, Schmiedel N, Palacio-Escat N, Chaves-Filho AB, Frias-Soler … · 2026-02-27

    cited 2× open access unreviewed
  9. 9
    A Novel CYP2E1 Inhibitor, 4-Methyl-5-Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and Mitochondrial Dysfunction.

    Qiu J, Gao L, Wang L, Wang X, Jia L, Deng M, Tang L, Wen Q, Gao N, Xu H, Qiao H. · 2025-12-20

    cited 2× open access unreviewed
  10. 10

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.